Abstract
The purpose of our study was to investigate the efficacy and toxicity of paclitaxel in patients with relapsed or refractory epithelial ovarian cancer in the context of a large multicentre study performed in the UK and Eire. Patients with previously treated epithelial carcinoma of the ovary or fallopian tube who fulfilled the eligibility criteria were entered in the study. Eligibility criteria included: measurable or evaluable disease; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; up to three prior chemotherapy regimens, one of which had to contain a platinum agent; adequate haematological, renal and hepatic function; and no significant cardiac history. Patients received either 175 mg m-2 or 135 mg m-2 paclitaxel. The lower dose was administered to patients who had received more than two prior chemotherapy regimens. Paclitaxel was given by i.v. infusion over 3 h every 21 days. Response was assessed at three-cycle intervals or earlier if required. A total of 155 patients were registered for the study in the UK of whom 140 were eligible for response and toxicity evaluation, and 12 patients were assessed for toxicity only. Hair loss was the most frequently reported toxicity, with 74% (119/152) of patients reporting grade 3 alopecia. The most frequently reported serious toxicity was neutropenia, with 49% (74/152) of patients experiencing neutropenia grade 3 or 4. The response rate was 16% [two complete responders (CR), 20 partial responders (PR)], the median duration of response was 275 days and median survival was 244 days. Paclitaxel is active in relapsed and platinum-resistant epithelial ovarian cancer. It is well tolerated and can be given in an out-patient setting. The UK and Eire experience is very similar to that of US investigators in this group of patients. Further work is required to assess the optimal use of the drug in both first- and second-line therapy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989 Apr;59(4):650–653. doi: 10.1038/bjc.1989.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Einzig A. I., Wiernik P. H., Sasloff J., Runowicz C. D., Goldberg G. L. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol. 1992 Nov;10(11):1748–1753. doi: 10.1200/JCO.1992.10.11.1748. [DOI] [PubMed] [Google Scholar]
- Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., Jones W., Almadrones L., Lewis J. L., Jr Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991 Mar;9(3):389–393. doi: 10.1200/JCO.1991.9.3.389. [DOI] [PubMed] [Google Scholar]
- McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
- Schiff P. B., Fant J., Horwitz S. B. Promotion of microtubule assembly in vitro by taxol. Nature. 1979 Feb 22;277(5698):665–667. doi: 10.1038/277665a0. [DOI] [PubMed] [Google Scholar]
- Thigpen J. T., Vance R. B., Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer. 1993 Feb 15;71(4 Suppl):1559–1564. doi: 10.1002/cncr.2820710422. [DOI] [PubMed] [Google Scholar]
- Trimble E. L., Adams J. D., Vena D., Hawkins M. J., Friedman M. A., Fisherman J. S., Christian M. C., Canetta R., Onetto N., Hayn R. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol. 1993 Dec;11(12):2405–2410. doi: 10.1200/JCO.1993.11.12.2405. [DOI] [PubMed] [Google Scholar]